Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 3/20 | 0.38 |
| ▸ | CCR3 | P51677 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | OXTR | P30559 | 2/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.34 |
| ▸ | GPR6 | P46095 | 5/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | UGCG | Q16739 | 1/20 | 0.34 |
| ▸ | CFD | P00746 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21752520 | 1.00 | IDO1 (0.47) | IDO1HRH1CCR3ALOX15GRIN2B | |
| SCHEMBL21752590 | 0.92 | IDO1 (0.52) | IDO1ALOX15KMT2ACFDSIGMAR1 | |
| SCHEMBL21752534 | 0.92 | IDO1 (0.52) | IDO1ALOX15KMT2ACFDSIGMAR1 | |
| SCHEMBL21752469 | 0.92 | IDO1 (0.52) | IDO1ALOX15KMT2ACFDSIGMAR1 | |
| SCHEMBL21752602 | 0.90 | IDO1 (0.52) | IDO1ALOX15KMT2ACFD | |
| SCHEMBL21752734 | 0.90 | IDO1 (0.52) | IDO1ALOX15KMT2ACFD | |
| SCHEMBL21752625 | 0.90 | IDO1 (0.52) | IDO1ALOX15KMT2ACFD | |
| SCHEMBL21752503 | 0.88 | HRH1 (0.40) | IDO1HRH1CCR3ALOX15GRIN2B | |
| SCHEMBL23959552 | 0.87 | GRIN2B (0.43) | HRH1CCR3ALOX15GRIN2BGPR6 | |
| SCHEMBL21752658 | 0.87 | HRH1 (0.39) | IDO1HRH1CCR3ALOX15GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576087-B2 | Aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-03-17 | — | — | US | claimed |
| EP-3840747-B1 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-03-29 | — | — | EP | claimed |
| US-20210330676-A1 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-10-28 | — | — | US | claimed |
| EP-3840747-A1 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-06-30 | — | — | EP | claimed |
| WO-2020041100-A1 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-27 | — | — | WO | claimed |
| US-12576087-B2 | Aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-03-17 | — | — | US | disclosed |
| EP-3840747-B1 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20210330676-A1 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-10-28 | — | — | US | disclosed |
| US-20210330676-A1 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576087-B2 | Aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, TPH1 | IDO1 1/4885HRH1 114/4885CCR3 164/4885 |
| US-20210330676-A1 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | IDO1, IDO2, KYNU | IDO1 1/4885HRH1 385/4885CCR3 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.